



Galileo Pharmaceuticals, Inc.
5301 Patrick Henry Drive
Santa Clara, CA 95054
galileopharma.com

RECEIVED
CENTRAL FAX CENTER

DEC 30 2003

Facsimile Transmission

OFFICIAL

Date: 30 December 2003

To: Director of the Office of Technology Center 1600
703-872-9306

From: Gloria Pfister
408 654 5830 x 237 (voice)
408 654 5831 (fax)

21 Pages

Transmitted:
Transmittal (2 pages)
IDS Form 1449
2 References (17 pages)
Fax cover sheet (1 page)

The information in this facsimile should be treated as confidential and is intended only for the use of the addressee specified above. It should be safeguarded from disclosure to others. If the reader is not the intended recipient, you are hereby notified that retention, verbal disclosure, copying, or otherwise disseminating this information is strictly forbidden by federal, state and local law. If you receive this fax in error, please notify the sender and return all copies to the address above.

+
CERTIFICATE OF MAILING

I hereby certify that this paper is being sent via facsimile to the Director of the Office of Technology Center 1600, FAX# 703-872-9306, on December 30, 2003.

Gloria Pfister
Gloria Pfister12/30/2003
Date: December 30, 2003**RECEIVED**
CENTRAL FAX CENTER**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

DEC 30 2003

In Re Application of:

Gilat, S. et al.

Attorney Docket No. 0126-UTL

Serial No. 10/696,752

Art Group:

Filed: October 29, 2003

Title: IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIESDirector of the USPTO
Alexandria, Virginia 22313-1450

Sir:

Transmittal Letter for Supplemental Information Disclosure Statement

Applicants wish to bring to the attention of the Examiner additional, recently published or discovered reference documents. The attached Information Disclosure Statement is filed in compliance with 37 CFI §1.56, and the documents cited therein may be material to the examination of the subject Application.

Attached is:

- (a) Form 1449, "List of References Cited"
- (b) 2 references (17 pages)

Certified Statement

This Supplemental Information Disclosure Statement is being before the mailing date of the first office action on the merits. Applicants' attorney hereby certifies under 37 CFR 1.97(e)(2) that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a foreign counterpart application, or, to the undersigned Attorney's knowledge after making reasonable inquiry, was known to any person designated in §1.56(c) more than three months prior to the filing of the Statement. Therefore, no fee is due under 37 CFR 1.97(c).

Information Disclosure Statement
Serial No.10/696,752


Case 0126-UTL
Page 2

Deposit Account Authorization

The Commissioner is hereby authorized to charge any additional fees or credit any overpayment to Deposit Account No. 50-2247. This is not an authorization to pay the issue fee.

The Examiner is respectfully requested to consider these documents and to make them of record in the subject application.

Respectfully submitted,



Gloria Pfister
Agent for Applicants
Registration No. 45,642

Galileo Pharmaceuticals
5301 Patrick Henry Drive
Santa Clara, CA 95054
Telephone No. (408) 654-5830 ex. 237

Date: December 30, 2003

PTO/SB/08B (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1448/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Complete if Known

Application Number	10/696,752
Filing Date	October 29, 2003
First Named Inventor	Gilat S
Art Unit	
Examiner Name	
Attorney Docket Number	0126-UTL

Sheet 1 of 1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	S1	LIVERTOUX, The superoxide production mediated by the redox cycling of xenobiotics in rat brain microsomes is dependent on their reduction...Brain research, 725, 207-216 (1996)	
	S2	HENDRICKSON, Relationship of flavonoid oxidation potential and effect on rat hepatic microsomal metabolism of benzene....J. Pharm. & Biomed. Analysis, 12,(3), 335-341 (1994)	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.